

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Chiglitazar Sodium,Metformin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Chiglitazar and Metformin Approved by NMPA for Type 2 Diabetes Treatment
Details : NMPA approved Chiglitazar, a noval PPAR (Peroxidase Proliferator Activated Receptor) full agonist developed by the company independently, combined with Metformin for the treatment of type 2 diabetes.
Product Name : Bilessglu
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 19, 2024
Lead Product(s) : Chiglitazar Sodium,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Chiglitazar Sodium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Results from Phase II Trial (CGZ203 Study) of Chiglitazar Monotherapy for NASH
Details : Bilessglu (chiglitazar sodium) is a novel peroxisome proliferator activation-related receptor pan-agonist, which is being evaluated for the treatment of non-alcoholic steatohepatitis.
Product Name : Bilessglu
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2024
Lead Product(s) : Chiglitazar Sodium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Chiglitazar Sodium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase II Clinical Trial of Chiglitazar for NASH
Details : Chiglitazar Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 18, 2022
Lead Product(s) : Chiglitazar Sodium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
